Spondyloarthropathies
News
Traditional risk factors raise cardiovascular risk in PsA
Key clinical point: The increased risk of cardiovascular disease in psoriatic arthritis is largely because of an increased prevalence of...
News
No increased risk of lung disease with methotrexate
Key clinical point: Methotrexate is not associated with an increased risk of pulmonary disease. Major finding: There was no increased risk of...
News
Rheumatologists support biosimilars, with caveats
News
Methotrexate and biologics linked to higher zoster risk in psoriasis
Key clinical point: The combination of methotrexate and biologics for the treatment of psoriasis may increase the risk of herpes zoster infection...
Conference Coverage
Secukinumab beat ustekinumab for psoriasis, with difference by week four
Key clinical point:Secukinumab achieved significantly better responses than ustekinumab in the treatment of moderate to severe psoriasis. Major...
Conference Coverage
Brodalumab achieved primary endpoints for moderate to severe psoriasis at 52 weeks
Key clinical point: At 52 weeks, brodalumab met its PASI 100 endpoint compared with ustekinumab in the pivotal phase III AMAGINE-2 trial. Major...
News
Halting biologics before surgery tied to flares in psoriasis, psoriatic arthritis
Key clinical point: Interrupting biologic therapy before surgery led to flares in psoriasis and psoriatic arthritis. Major finding: Discontinuing...
News
Interleukin-23 inhibition with tildrakizumab achieves significant psoriasis improvements
Conference Coverage
Acute anterior uveitis? Consider axial spondyloarthritis
News
Infliximab most common cause of drug-induced liver injury
Key clinical point: Infliximab was the most common anti–tumor necrosis factor-alpha agent linked to liver injury. Major finding: Rates of drug-...